13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002011932
Total reported value
$162.1M
$162.1M
52 檔
16.8%
As reported in its official Q2 2024 Form 13F filing, Exome Asset Management LLC's tracked investment portfolio stood at $162.1M with 52 total positions.
During Q2 2024, Exome Asset Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including LLY, SRPT, ONC) accounted for 16.8% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 7.82% | +0.72% | — | |
| 2 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 4.63% | — | — | |
| 3 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.22% | — | -9.78% | |
| 4 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 3.99% | +5.59% | NEW | |
| 5 | CI | THE Cigna Group | Stock-Healthcare | 3.59% | — | -20.26% | |
| 6 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 3.42% | -0.07% | -3.48% | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 3.39% | -1.34% | -20.78% | |
| 8 | AMGN | Amgen Inc | Stock-Healthcare | 3.28% | — | — | |
| 9 | TVTX | Travere Therapeutics Inc | Stock-Other | 3.24% | — | +22.32% | |
| 10 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.69% | — | +36.71% | |
| 11 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 2.62% | — | — | |
| 12 | DXCM | Dexcom Inc | Stock-Healthcare | 2.62% | — | +4.43% | |
| 13 | AUTL | Autolus Therapeutics PLC | Stock-Other | 2.60% | — | — | |
| 14 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 2.52% | -0.32% | — | |
| 15 | RDY | Dr. Reddy's Laboratories-adr | Stock-Other | 2.46% | — | -57.79% | |
| 16 | IRON | Disc Medicine Inc | Stock-Other | 2.45% | — | — | |
| 17 | ASND | Ascendis Pharma A/S | Stock-Other | 2.43% | — | — | |
| 18 | KURA | Kura Oncology Inc | Stock-Other | 2.42% | — | — | |
| 19 | ✓ | Merus N V | Stock-Other | 2.38% | — | — | |
| 20 | MASI* | Masimo CORP | Stock-Other | 2.22% | — | — | |
| 21 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.21% | — | — | |
| 22 | WVE | Wave Life Sciences Ltd. | Stock-Other | 2.17% | — | — | |
| 23 | GH | Guardant Health Inc | Stock-Healthcare | 2.03% | +2.30% | — | |
| 24 | CABA | Cabaletta Bio Inc | Stock-Other | 2.00% | — | — | |
| 25 | ARVN | Arvinas Inc | Stock-Other | 1.95% | — | — | |
| 26 | NTRA | Natera Inc | Stock-Healthcare | 1.80% | +0.38% | — | |
| 27 | BHVN | Biohaven Ltd. | Stock-Other | 1.79% | — | — | |
| 28 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.78% | -1.75% | +61.67% | |
| 29 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.67% | — | — | |
| 30 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.60% | -1.78% | EXIT | |
| 31 | ATEC | Alphatec Holdings Inc | Stock-Other | 1.51% | — | — | |
| 32 | ABCL | Abcellera Biologics Inc | Stock-Other | 1.36% | — | — | |
| 33 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.34% | — | +32.77% | |
| 34 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.19% | — | — | |
| 35 | RZLT | Rezolute Inc | Stock-Other | 1.08% | — | — | |
| 36 | ALVO | Alvotech | Stock-Other | 1.07% | — | — | |
| 37 | GOSS | Gossamer Bio Inc | Stock-Other | 0.90% | — | — | |
| 38 | ✓ | Elevation Oncology Inc | Stock-Other | 0.89% | — | — | |
| 39 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.88% | +0.31% | — | |
| 40 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.73% | — | — | |
| 41 | QTRX | Quanterix CORP | Stock-Other | 0.70% | — | — | |
| 42 | QTTB | Q32 Bio Inc | Stock-Other | 0.70% | — | -32.54% | |
| 43 | VYNE | Vyne Therapeutics Inc | Stock-Other | 0.62% | — | -14.92% | |
| 44 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.52% | — | — | |
| 45 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.50% | — | — | |
| 46 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.47% | — | — | |
| 47 | ADAG | Adagene Inc-adr | Stock-Other | 0.41% | -0.22% | -2.90% | |
| 48 | NBP | Novabridge Biosciences | Stock-Other | 0.40% | -0.04% | -16.69% | |
| 49 | ✓ | Procaps Group SA | Stock-Other | 0.29% | — | — | |
| 50 | ✓ | Hillevax Inc | Stock-Other | 0.23% | — | — |
According to official SEC Form 13F filings, Exome Asset Management LLC reported a total U.S. public equity portfolio value of $162.1M across 52 disclosed positions in Q2 2024.
During Q2 2024, Exome Asset Management LLC's top holdings by market value included LLY (7.8%)、SRPT (4.6%)、ONC (4.2%). The largest single position, LLY, represented 7.8% of total portfolio value.
In Q2 2024, Exome Asset Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.